The flavone apigenin has been tested in a 2 × FAD model (AD-linked mutations in APP and PS1), where oral administration (40 mg/kg/day) for 12 weeks beginning at 4 months of age resulted in improved learning and memory, reduced deposition of insoluble Aβ, a decrease in markers of oxidative stress, and an increase in the activity of the ERK-CREB pathway, an indicator of neurotrophic activity [41]. The gene discussed is PSEN1; the disease is Alzheimer disease.